Drummer C, Valta-Seufzer U, Spannagl M, Frey A, Lüdke S, Schramm W, Gerzer R
Medizinische Klinik, Klinikum Innenstadt der Universität München.
Z Kardiol. 1991;80 Suppl 5:43-6.
Twelve healthy volunteers received either a single oral dose of molsidomine (4 mg), isosorbide-5-mononitrate (ISMN, 20 mg), or placebo in a randomized, double-blind fashion. Blood was drawn prior to, as well as 30 and 60 min after intake of the respective drug. Platelet aggregation and the plasma levels/activity of plasminogen activator (tPA) and its inhibitor (PAI-1) were determined. In contrast to ISMN and placebo, molsidomine provoked a significant reduction in platelet aggregability. No alteration in plasma tPA concentrations was observed independent of whether molsidomine, ISMN, or placebo was applied. However, plasma PAI-1 activity was considerably reduced following molsidomine, but not altered following ISMN or placebo. We conclude that a single oral dose of molsidomine, but not of ISMN inhibits platelet aggregation and increases the fibrinolytic potential in healthy volunteers.
12名健康志愿者以随机、双盲方式接受单次口服剂量的莫西多明（4毫克）、5-单硝酸异山梨酯（ISMN，20毫克）或安慰剂。在服用相应药物之前以及之后30分钟和60分钟采集血液。测定血小板聚集以及纤溶酶原激活物（tPA）及其抑制剂（PAI-1）的血浆水平/活性。与ISMN和安慰剂不同，莫西多明引起血小板聚集性显著降低。无论应用莫西多明、ISMN还是安慰剂，均未观察到血浆tPA浓度有改变。然而，莫西多明给药后血浆PAI-1活性显著降低，但ISMN或安慰剂给药后未改变。我们得出结论，单次口服剂量的莫西多明而非ISMN可抑制健康志愿者的血小板聚集并增加纤溶潜力。
